Recently details of the LUXLung 8 phase 3 trial became available. This study compared afatinib with erlotinib as second-line treatment for squamous cell carcinoma of the lung.
Afatinib was better with respect to all parameters – median progression-free survival, overall survival and patient-reported quality of life outcome (using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 LC13).
Rates of improved global health status/quality of life (35.7% vs 28.3%; P = .041) and cough (43.4% vs 35.2%; P = .029) were significantly greater with afatinib than erlotinib.?
Afatinib significantly delayed time to deterioration of dyspnea versus erlotinib (2.6 vs 1.9 months; P = .008), with a trend toward delayed time to deterioration of cough with afatinib.
Changes in mean scores over time favored afatinib over erlotinib significantly for cough (P = .0091), dyspnea (P = .0024), and pain (P = .0384).
This is how we improve quality of life and survival for patients with lung cancer.